Dr. Reedy welcomes Dr. Alexa Altman where she discusses how psychedelics bring the unconscious material into consciousness. She talks about the importance of integration.

Dr. Altman’s Website: https://www.i-psychedelic.com

1. Single-dose psilocybin (25 mg) with psychological support for MDDJAMA – “Single-Dose Psilocybin Treatment for Major Depressive Disorder” psychiatryonline.org+15sunstonetherapies.com+15pmc.ncbi.nlm.nih.gov+15 Summary: Demonstrated strong antidepressant effects and good tolerability over follow-up. Email: [email protected]

2. One-Year Follow-Up of Psilocybin for Depression

Study: Long-term effects of psilocybin therapy for depression

Johns Hopkins – “Psilocybin treatment for major depression effective for up to a year” Summary: 67% of participants remained in remission one year post-treatment.

3. MDMA-Assisted Therapy for Severe PTSD

Randomized, placebo-controlled MDMA-assisted therapy

Nature Medicine – “MDMA-assisted therapy for severe PTSD” Summary: Significant reduction in PTSD symptoms, well‑tolerated in a diverse cohort.

Contact (MAPS / Lykos Therapeutics): Email: [email protected]

4. Psilocybin for Cancer-Related Anxiety & Depression

Psilocybin in patients with life-threatening cancer

PMC – “High-dose psilocybin produced large decreases in depressed mood and anxiety…” Summary: 80% of participants maintained significant symptom relief at 6 months. Website: heffter.org (contact via site) en.wikipedia.org

1. Johns Hopkins University

Center for Psychedelic and Consciousness Research

Psilocybin for depression, anxiety, addiction, and end-of-life distress

Why it’s top-tier: The first major U.S. institution to receive regulatory approval for psychedelic research in modern times. 🔗 hopkinspsychedelic.org

2. Imperial College London

Centre for Psychedelic Research

Psilocybin for treatment-resistant depression, brain imaging, DMT studies

Why it’s top-tier: Home of pioneering neuroimaging studies on psychedelics; led by Robin Carhart-Harris (now at UCSF). 🔗 imperial.ac.uk

3. Multidisciplinary Association for Psychedelic Studies (MAPS)

MDMA for PTSD (now in Phase 3 trials), harm reduction, global education

Why it’s top-tier: MAPS initiated the first FDA-approved Phase 3 trials for MDMA-assisted therapy. 🔗 maps.org

4. University of California, San Francisco

Psychedelic Research Program

Psilocybin, DMT, ibogaine; Robin Carhart-Harris now leads U.S. arm

Why it’s top-tier: Integrates neuroscience, clinical psychology, and pharmacology. 🔗 psychedelics.ucsf.edu

5. NYU Langone Health

Center for Psychedelic Medicine

End-of-life anxiety, alcoholism, PTSD, and psilocybin studies

Why it’s top-tier: Known for rigorous clinical trials and major collaborations. 🔗 med.nyu.edu

6. University of California, Los Angeles

UCLA Psychedelic Studies Initiative

Psilocybin + CBT, anxiety, clinical protocols

Why it’s top-tier: Conducting one of the few FDA-regulated psilocybin trials with integrated therapy. 🔗 uclapsi.org

7. University of Wisconsin–Madison / Usona Institute

Psilocybin for major depression (FDA Phase 3 trials)

Why it’s top-tier: Leading U.S.-based nonprofit with regulatory traction and major academic partnerships. 🔗 usonainstitute.org

8. Massachusetts General Hospital / Harvard Medical School

Center for the Neuroscience of Psychedelics

Neurobiological mechanisms of psychedelics

Why it’s top-tier: Combines Harvard academic leadership with Mass General clinical infrastructure. 🔗 massgeneral.org

9. University of New Mexico

Psychedelic-Assisted Therapies & Research Group

Ketamine, DMT, and MDMA research; Indigenous-informed approaches

Why it’s top-tier: Interdisciplinary and trauma-informed program with cultural awareness. 🔗 hsc.unm.edu

10. Oregon Health & Science University

State-licensed psilocybin therapy programs, public health, training

Why it’s top-tier: One of the first institutions engaging with psilocybin therapy post-legalization under Measure 109. 🔗 ohsu.edu